Search research articles
Contact Us
Filters
Showing results (101-110 of 141) with videos related to
Page
of 15
Sort By:
Journal of the National Cancer Institute
|
April 3, 2024
TP53-associated early breast cancer: new observations from a large cohort
Renata L Sandoval, Michele Bottosso, Li Tianyu, et al.
Breast Cancer Research and Treatment
|
September 24, 2021
Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue
Pietro Lapidari, Nardjes Djehal, Julie Havas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy
Gail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Breast (Edinburgh, Scotland)
|
March 12, 2021
Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer
Pietro Lapidari, Arnauld Gbenou, Julie Havas, et al.
Cancer Discovery
|
October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.
Psycho-Oncology
|
October 14, 2020
Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohort
Isabelle Hardy-Leger, Cécile Charles, Marie Lange, et al.
Molecular Cancer
|
November 4, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, et al.
The Lancet. Oncology
|
March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
The Lancet. Oncology
|
March 3, 2007
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
Yun Gong, Kai Yan, Feng Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2019
Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)
Agnes Dumas, Ines Vaz Luis, Thomas Bovagnet, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 141) with videos related to
Sort By:
Page
of 15
Journal of the National Cancer Institute
|
April 3, 2024
TP53-associated early breast cancer: new observations from a large cohort
Renata L Sandoval, Michele Bottosso, Li Tianyu, et al.
Breast Cancer Research and Treatment
|
September 24, 2021
Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue
Pietro Lapidari, Nardjes Djehal, Julie Havas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy
Gail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Breast (Edinburgh, Scotland)
|
March 12, 2021
Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer
Pietro Lapidari, Arnauld Gbenou, Julie Havas, et al.
Cancer Discovery
|
October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.
Psycho-Oncology
|
October 14, 2020
Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohort
Isabelle Hardy-Leger, Cécile Charles, Marie Lange, et al.
Molecular Cancer
|
November 4, 2023
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, et al.
The Lancet. Oncology
|
March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
The Lancet. Oncology
|
March 3, 2007
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
Yun Gong, Kai Yan, Feng Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2019
Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)
Agnes Dumas, Ines Vaz Luis, Thomas Bovagnet, et al.
Page
of 15